On the use of sham transcutaneous spinal cord stimulation in spinal cord injury clinical trials.
Where this comes from
- Record sourced from PubMed, PMID 39901727.
- Also identified by DOI 10.1093/brain/awaf040 and PMC identifier 12073991.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Kramer <i>et al.</i> examine the reasons put forth by investigators for excluding a sham condition in trials of neuromodulation therapies for individuals with spinal cord injury. They conclude that current dogma does not justify this design, and emphasize the need for future trials to include appropriate controls.